As of December 2024, the dosage forms of medicines for COVID-19 treatment are tablets and capsules. These unit-dose solid dosage forms offer several advantages, including ease of storage, portability, ease of administration, and accuracy in dosing. Limenh et al. found that participants in a clinical study preferred tablets over capsules (42.4% vs. 19.9%). Therefore, we selected tablets as the to-be-marketed formulation of S-892216. On the basis of previous results, we employed spray drying to enhance drug solubility and dry granulation to prepare the to-be-marketed formulation. Dry granulation is a common process in the manufacture of solid dispersion formulations.